MOA Life Plus Co. Ltd. (KOSDAQ:142760)

South Korea flag South Korea · Delayed Price · Currency is KRW
622.00
-43.00 (-6.47%)
At close: Mar 9, 2026
-50.44%
Market Cap 25.38B
Revenue (ttm) 9.80B
Net Income (ttm) -11.86B
Shares Out 40.81M
EPS (ttm) -339.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 188,893
Average Volume 1,880,114
Open 665.00
Previous Close 665.00
Day's Range 600.00 - 669.00
52-Week Range 577.00 - 2,250.00
Beta 1.03
RSI 17.38
Earnings Date Mar 20, 2026

About MOA Life Plus

MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug. The company’s pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and BLS-M22 that has completed phase 1 clinical trial for the treatment of Duchenne muscular dystrophy. It also provides health functional food and raw ma... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Employees 42
Stock Exchange KOSDAQ
Ticker Symbol 142760
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.